AGEN

Agenus
AGEN

$4.95

1%

Market Cap: $107M

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 389

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,235% more call options, than puts

Call options by funds: $42.6M | Put options by funds: $3.19M

420% more capital invested

Capital invested by funds: $157M [Q1] → $815M (+$659M) [Q2]

7.92% less ownership

Funds ownership: 49.59% [Q1] → 41.67% (-7.92%) [Q2]

30% less funds holding

Funds holding: 125 [Q1] → 88 (-37) [Q2]

57% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 65

97% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 58

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

39%

downside

Avg. target

$17.50

254%

upside

High target

$40

708%

upside

4 analyst ratings

2 positive

50%

2 neutral

50%

0 negative

0%

B. Riley Securities Yuan Zhi 40% 1-year accuracy 4 / 10 met price target	264%upside $18	Buy Maintained	14 Aug 2024
Jefferies Biren Amin 57% 1-year accuracy 8 / 14 met price target	39%downside $3	Hold Downgraded	19 Jul 2024
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 30 / 108 met price target	82%upside $9	Neutral Downgraded	18 Jul 2024
HC Wainwright & Co. Emily Bodnar 28% 1-year accuracy 30 / 108 met price target	708%upside $40	Buy Reiterated	28 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 37 articles about AGEN published over the past 30 days

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming Deadlines - AGEN

NEW YORK, NY / ACCESSWIRE / September 7, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming Deadlines - AGEN

Agenus Inc Is Being Looked Into For Committing Securities Fraud And The Schall Law Firm Wants Investors To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc Is Being Looked Into For Committing Securities Fraud And The Schall Law Firm Wants Investors To Reach Out

Pomerantz Law Firm Announces the Filing of a Class Action Against Agenus Inc. and Certain Officers - AGEN

NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Agenus Inc. and Certain Officers - AGEN

Stockholders With Losses In Agenus Inc. Are Invited To Join The Schall Law Firm's Investigation Into Possible Fraud

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stockholders With Losses In Agenus Inc. Are Invited To Join The Schall Law Firm's Investigation Into Possible Fraud

Agenus Inc May Have Committed Securities Related Impropriety And Investors Should Contact The Schall Law Firm About An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc May Have Committed Securities Related Impropriety And Investors Should Contact The Schall Law Firm About An Inquiry

The Schall Law Firm Wants Stakeholders To Partake In An Investigation Into Agenus Inc.'s Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Stakeholders To Partake In An Investigation Into Agenus Inc.'s Possible Securities Fraud

Agenus Inc Is Being Looked Into For Possibly Violating Securities Laws And Investors Are Urged By The Schall Law Firm To Participate

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc Is Being Looked Into For Possibly Violating Securities Laws And Investors Are Urged By The Schall Law Firm To Participate

Agenus to Participate in September Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference: Fireside chat will be held in-person on Thursday, September 5th at 1.

Agenus to Participate in September Investor Conferences

Stakeholders In Agenus Inc. Should Reach Out To The Schall Law Firm About Joining A Securities Related Investigation

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stakeholders In Agenus Inc. Should Reach Out To The Schall Law Firm About Joining A Securities Related Investigation

Agenus Inc May Have Committed Securities Fraud And The Schall Law Firm Seeks Investors' Assistance With An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc May Have Committed Securities Fraud And The Schall Law Firm Seeks Investors' Assistance With An Inquiry

See News Rankings